Trials / Unknown
UnknownNCT05920668
Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Wang Xin · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a multicenter observational study of Orelabrutinib in the treatment of CLL/SLL. Patients were treated with Orelabrutinib for 12 cycles. The primary end points were grade 3 hypertension and incidence of atrial fibrillation, and the secondary end points were improvement in abnormal markers, ORR,CR,PFS, and OS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib | Orelabrutinib monotherapy for CLL/SLL 12 cycles |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2024-07-01
- Completion
- 2025-07-01
- First posted
- 2023-06-27
- Last updated
- 2023-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05920668. Inclusion in this directory is not an endorsement.